NCT03071133View on ClinicalTrials.gov

Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy

CompletedOBSERVATIONAL
Enrollment

344

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 8, 2019

Study Completion Date

January 8, 2019

Conditions
Hepatitis C
Trial Locations (1)

1620814

Local Institution, Tokyo

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03071133 - Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy | Biotech Hunter | Biotech Hunter